Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Palacios, J.
Right arrow Articles by Benítez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Palacios, J.
Right arrow Articles by Benítez, J.
Clinical Cancer Research Vol. 9, 3606-3614, September 1, 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Immunohistochemical Characteristics Defined by Tissue Microarray of Hereditary Breast Cancer Not Attributable to BRCA1 or BRCA2 Mutations

Differences from Breast Carcinomas Arising in BRCA1 and BRCA2 Mutation Carriers1

José Palacios2, Emiliano Honrado, Ana Osorio, Alicia Cazorla, David Sarrió, Alicia Barroso, Sandra Rodríguez, Juan C. Cigudosa, Orland Diez, Carmen Alonso, Enrique Lerma, Lydia Sánchez, Carmen Rivas and Javier Benítez

Laboratory of Breast and Gynecological Cancer [J. P., D. S.], Human Genetics Department [E. H., A. O., A. B., S. R., J. C. C., J. B.], Cytogenetics Unit [S. R., J. C. C.], Immunohistological Unit, Centro Nacional de Investigaciones Oncológicas, 28029 Madrid [L. S.]; Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma, Madrid [A. C., C. R.]; and Department of Genetics [O. D.], Oncology [C. A.], and Pathology [E. L.], Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Purpose: Most familial breast cancers are not associated with BRCA1 or BRCA2 germ-line mutations. Therefore, it is of major importance to define the morphological, immunohistochemical, and molecular features of this group of tumors to improve genetic testing and also gain further insight into the biological characteristics of tumors.

Experimental Design: We evaluated the morphological characteristics of 37 tumors arising in women without BRCA1 or BRCA2 mutations, 20 tumors from BRCA1 mutation carriers, and 18 from BRCA2 mutation carriers, all of which were from index patients from breast cancer families. In addition, a tissue microarray was constructed with all tumoral samples to evaluate the immunohistochemical expression of a wide panel of antibodies (11 antibodies) and the amplification of HER-2 and c-MYC genes by fluorescence in situ hybridization. An age-matched group with 50 sporadic breast cancers as controls for non-BRCA1/2 was also included.

Results: Non-BRCA1/2 infiltrating ductal carcinomas (IDCs) showed specific differences from BRCA1 tumors. They were of lower grade (1 and 2); more frequently estrogen receptor, progesterone receptor, BCL2 positive, and p53 negative; had a low proliferation rate (Ki-67 immunostaining < 5%); and did not express P-cadherin. With respect to BRCA2 IDCs and control group, non-BRCA1/2 tumors were of lower grade and had a lower proliferation rate. No cases of HER-2 amplification and/or overexpression were observed except in the control group (~20%). In contrast, c-MYC amplification was present in 18.2, 62.5, and 12.5% of BRCA1, BRCA2, and non-BRCA1/2 IDCs, respectively, and 31% in the control group.

Conclusions: This study thus reveals distinct morphological and immunohistochemical features in non-BRCA1/2 and BRCA1 tumors, whereas BRCA2 tumors present characteristics intermediate between the two phenotypes. In addition, the study also demonstrates the usefulness of tissue microarray technology in the evaluation of the immunophenotypic features of hereditary breast cancer.




This article has been cited by other articles:


Home page
JCOHome page
E. A. Rakha, J. S. Reis-Filho, and I. O. Ellis
Basal-Like Breast Cancer: A Critical Review
J. Clin. Oncol., May 20, 2008; 26(15): 2568 - 2581.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Aaltonen, C. Blomqvist, R.-M. Amini, H. Eerola, K. Aittomaki, P. Heikkila, and H. Nevanlinna
Familial Breast Cancers without Mutations in BRCA1 or BRCA2 Have Low Cyclin E and High Cyclin D1 in Contrast to Cancers in BRCA Mutation Carriers
Clin. Cancer Res., April 1, 2008; 14(7): 1976 - 1983.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Melchor, E. Honrado, J. Huang, S. Alvarez, T. L. Naylor, M. J. Garcia, A. Osorio, D. Blesa, M. R. Stratton, B. L. Weber, et al.
Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast Cancer
Clin. Cancer Res., December 15, 2007; 13(24): 7305 - 7313.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. R. James, J. E. Quinn, P. B. Mullan, P. G. Johnston, and D. P. Harkin
BRCA1, a Potential Predictive Biomarker in the Treatment of Breast Cancer
Oncologist, February 1, 2007; 12(2): 142 - 150.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. A. Oldenburg, K. Kroeze-Jansema, H. Meijers-Heijboer, C. J. van Asperen, N. Hoogerbrugge, I. van Leeuwen, H. F.A. Vasen, A.-M. Cleton-Jansen, J. Kraan, J. J. Houwing-Duistermaat, et al.
Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping.
Clin. Cancer Res., March 15, 2006; 12(6): 1693 - 1700.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Melchor, S. Alvarez, E. Honrado, J. Palacios, A. Barroso, O. Diez, A. Osorio, and J. Benitez
The Accumulation of Specific Amplifications Characterizes Two Different Genomic Pathways of Evolution of Familial Breast Tumors
Clin. Cancer Res., December 15, 2005; 11(24): 8577 - 8584.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Honrado, A. Osorio, J. Palacios, R. L. Milne, L. Sanchez, O. Diez, A. Cazorla, K. Syrjakoski, D. Huntsman, P. Heikkila, et al.
Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer Differentiate BRCA2-Associated Tumors
J. Clin. Oncol., October 20, 2005; 23(30): 7503 - 7511.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. B. Arnes, J.-S. Brunet, I. Stefansson, L. R. Begin, N. Wong, P. O. Chappuis, L. A. Akslen, and W. D. Foulkes
Placental Cadherin and the Basal Epithelial Phenotype of BRCA1-Related Breast Cancer
Clin. Cancer Res., June 1, 2005; 11(11): 4003 - 4011.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Collett, I. M. Stefansson, J. Eide, A. Braaten, H. Wang, G. E. Eide, S. O. Thoresen, W. D. Foulkes, and L. A. Akslen
A Basal Epithelial Phenotype Is More Frequent in Interval Breast Cancers Compared with Screen Detected Tumors
Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1108 - 1112.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. H. van Beers, T. van Welsem, L. F.A. Wessels, Y. Li, R. A. Oldenburg, P. Devilee, C. J. Cornelisse, S. Verhoef, F. B.L. Hogervorst, L. J. van't Veer, et al.
Comparative Genomic Hybridization Profiles in Human BRCA1 and BRCA2 Breast Tumors Highlight Differential Sets of Genomic Aberrations
Cancer Res., February 1, 2005; 65(3): 822 - 827.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J. Palacios, E. Honrado, A. Osorio, O. Diez, C. Rivas, and J. Benitez
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
J Natl Cancer Inst, May 5, 2004; 96(9): 712 - 714.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.